

# Financial Results for Q3 2025

Controlling net income on a YTD basis reached **COP 2.5 trillion**, of which **COP 2.1 trillion** is recurring net income.

- This reflects our strategy of consolidating a portfolio focusing on the financial service sector.

## Consolidated figures


Stated in COP billions

### Pro forma Controlling Net Income<sup>1</sup>




<sup>1</sup> Adjusted figures that exclude non-recurring effects from the Nutresa exchange in 2024, the profit associated with the spin-off by absorption, and the increase in the liability related to preferred shares issued in 2025. The historical equity-method contribution from Grupo Argos is also excluded to reflect only the financial portfolio and EPS SURA.

### Pro forma net income Breakdown<sup>2</sup>



Administrative calculation of net earnings per share is based on number of shares at the end of each period.  
<sup>2</sup> Adjusted data excludes non-recurring effects of the Nutresa share swap (2023-2024), the gain associated with the spin-off by absorption and the increase in the liability for preferred shares issued in 2025. The historical equity method formerly relating to Grupo Argos and Grupo Nutresa is also excluded to reflect only our financial portfolio and the EPS SURA healthcare subsidiary throughout the series.

### Recurring earnings per share<sup>3</sup>



<sup>3</sup> Earnings per share are adjusted for the healthcare subsidiary EPS SURA, the non-recurring effects of the Nutresa share swap (2023-2024), the profit associated with the spin-off by absorption (2025) and the increase in the liability for preferred shares as issued in 2025.

### Return on equity (Adjusted ROE)<sup>4</sup>



<sup>4</sup> Adjusted ROE corresponding to Grupo SURA, excludes the amortization of intangibles from acquisitions; the equity investment in Grupo Argos (due to not applying the equity method since 2025), non-recurring earnings (the Nutresa share swap 2024, the spin-off by absorption, the increase in the liability relating to preferred shares in 2025) and the healthcare subsidiary EPS SURA in 2024. Please refer to attachments relating to the calculation of ROE for 2025.



"At Grupo SURA, we continue advancing in our evolution and are reporting these results, which are the first since becoming an organization focused on a portfolio of financial companies. The solid figures recorded, as well as the positive appreciation of our shares, demonstrate the materialization of the various benefits we announced when presenting the spin-off by absorption. All these developments reinforce the strong position of the company and motivate us to keep working on building and generating value for our shareholders."

**Ricardo Jaramillo Mejía**  
CEO Grupo SURA

## Our portfolio is now focused on the financial service sector

YTD figures at the end of Q3 2025

**suramericana**

Controlling net income (Proforma)  
**COP 655 billion** ↑ 3.1%

Adjusted ROE<sup>1</sup> **12.7%**

Written premiums (Proforma)  
**COP 14,447 billion** ↑ 4.9%

Changes per insurance segment

Life **12.3%** ↑

Property and casualty **1.7%** ↓

<sup>1</sup> Adjusted ROE on a LTM basis excludes the amortization of intangibles. ROE for 2024 excludes the effects of the divestitures in Argentina and El Salvador in 2023. The healthcare subsidiary, EPS SURA is excluded for the year 2024.

**SURA**  
ASSET MANAGEMENT

Net income  
**COP 1,088 billion** ↑ 24.4%

Adjusted ROE<sup>2</sup> **10.6%**

Assets under management (AUM)<sup>3</sup>  
**COP 813 trillion** ↑ 15.6%

Fee and commission income  
**COP 3,177 billion** ↑ 10.8%

Changes per segment

Savings and retirement **10.0%** ↑

SURA Investments **17.2%** ↑

<sup>2</sup> ROE and adjusted ROTE exclude acquisition-related intangible amortization expense.  
<sup>3</sup> AUM excludes El Salvador in 2024.

### Grupo Cibest



## Ambitions 2028

	Sept. 2025 Last 12 months	2028 Estimated
Net income <b>UPA(COP)</b>	2.3 trillions <b>7,132</b>	~3.3 trillions <b>~10,000</b>
Adjusted ROE	13.8%	~15%
Net debt <b>Net debt / dividend</b>	7.1 trillions <b>3.2x</b>	<5 trillions <b>~2x</b>
Dividend per share (COP)	1,500	~3,000

2028 ambitions estimated with organic growth and without extraordinary events

## Quarterly Highlights

**Merco Companies**

In the most recent edition of Merco Empresas 2025, Grupo SURA ranked fourth in the Colombia assessment, rising one position and reflecting the trust that SURA companies receive from their various stakeholders.

**MSCI inclusion**

The entity officially announced that Grupo SURA's preferred shares will be incorporated into the MSCI Colombia Small Cap Index as of the market close on November 30, 2025. According to the firm, this inclusion reflects a favorable environment for the Colombian equity market, highlighting Grupo SURA's performance on the Colombian Stock Exchange.

**Creating value with every action**

Insurance | Savings | Banking | Investment